Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05382208 · ClinicalTrials.gov registry record · Phase 2
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
A Phase 2 study of HIV and Emphysema, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 20
- Study locations
NCT05382208: Active Phase 2 study of HIV and Emphysema, sponsored by Weill Medical College of Cornell University.
NCT05382208 is a Phase 2 study of HIV and Emphysema that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 133 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05382208, a Phase 2 study of HIV and Emphysema, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections.
Interventions
- DRUG Placebo
- DRUG Doxycycline
Study Locations (20)
Ohio
- University of Cincinnati College of Medicine - Cincinnati
- Case Western University - Cleveland
- Ohio State University - Columbus
California
- University of California Los Angeles - Los Angeles
- University of California San Diego - San Diego
New York
- SUNY Downstate Medical School - Brooklyn
- Weill Cornell Medicine - New York
North Carolina
- University of North Carolina - Chapel Hill
- Duke University School of Medicine - Durham
Pennsylvania
- Temple University - Philadelphia
- University of Pittsburgh - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- Miami University - Miami
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2022-08-22 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What the registry record for NCT05382208 still lists
NCT05382208 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05382208 names 20 study sites across 14 states, led by Ohio, California, New York.
Frequently Asked Questions
What is clinical trial NCT05382208 about?
NCT05382208 is a clinical study titled "Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)". The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expira...
What is the current status of trial NCT05382208?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2022-08-22. Estimated completion is 2027-02.
What conditions does trial NCT05382208 study?
This clinical trial studies the following conditions: HIV, Emphysema.
What interventions are being tested in trial NCT05382208?
The interventions under investigation include: Placebo (DRUG), Doxycycline (DRUG).
Who is sponsoring clinical trial NCT05382208?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05382208 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05382208's enrollment target sits among peer trials
133 138th of 303 higher than 166 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Improving Physical Ability and Cellular Senescence Elimination in HIV
RECRUITING · Phase 2
-
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
RECRUITING · Phase 2
-
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI